Just reported
From Merck's results release of 2026年10月29日; its quarterly report has since been filed.
Actual
$18.09B
+4.7% y/y
+8.9% q/q
Guided
—
No guide given
Actual
$2.04
-12% y/y
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →売上構成比はFY2025の推計であり、提出された報告書の数字ではありません。
Keytruda and Keytruda Qlex
Cancer medicines. Keytruda is given into a vein; Keytruda Qlex is a form given as an injection under the skin.
Gardasil and Gardasil 9
Vaccines that help prevent certain cancers and other diseases caused by some types of human papillomavirus.
Januvia and Janumet
Prescription medicines used to help lower blood sugar in adults with type 2 diabetes.
Winrevair
A medicine for adults with pulmonary arterial hypertension, a disease that raises blood pressure in the arteries from the heart to the lungs.
Lipfendra
An oral medicine used with diet and exercise to lower low-density lipoprotein cholesterol in adults with high cholesterol.
Bravecto
A range of medicines that protect dogs and cats against fleas and ticks, including oral, topical and injectable forms.
Merck discovers, develops, manufactures and sells prescription medicines and vaccines for people, including cancer treatments such as Keytruda and vaccines such as Gardasil. Its Animal Health business sells medicines, vaccines and animal identification and monitoring products to veterinarians, farmers and other animal-care businesses.
Merck & Co., Inc. 自身が米国証券取引委員会(SEC)に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
$147.76+0.6%11月13日 終値
2026年9月30日までの数値(2026年11月4日提出の10-Qより)
Merck makes prescription medicines and vaccines for people, and medicines, vaccines and monitoring products for animals.
The themes Merck is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A
株価の下の帯は各日付時点の評価で、その時点までに公開された書類だけで算出しています。
Merck & Co., Inc. の評価履歴 41 四半期のうち 2 四半期を表示しています。 残る 39 四半期は 2016年11月 まで遡ります。